Over 100 new genomic regions linked to blood pressure were discovered, offering insights into iron metabolism and potential ...

Hypertension: By combining the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and ...

This came after Eris Lifescience presented the proposal along with the Phase III clinical trial report before the committee.

Treatment of overactive bladder can be more complex in the context of benign prostatic hyperplasia, but a new trial met ...

Researchers at the University of Houston College of Pharmacy have discovered that when a higher amount of a protein called ...

National Institutes of Health researchers and collaborators have discovered over 100 new regions of the human genome, also ...

In February 2024, Ocuphire appointed Nirav Jhaveri, C.F.A, M.B.A., as Chief Financial Officer and Ashwath (Ash) Jayagopal, Ph.D., M.B.A., as Chief Scientific and Development Officer.

Discover how Vanda Pharmaceuticals' patent revolutionizes circadian rhythm disorder treatment with tasimelteon, tailored to patients' beta-adrenergic receptor antagonist use.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion and ...

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways ...

National Institutes of Health researchers and collaborators have discovered over 100 new regions of the human genome, also known as genomic loci, that appear to influence a person’s blood pressure.